Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Altimmune, Inc.NASDAQ: ALT
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital dips below year-ago levels
Q1 FY2026 other working capital of $876K (cash outflow) fell 58.8% year over year, behind the +343700.0% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at -35.2% a year.
Context
- Other working capital amounted to 5329.3% of revenue in FY2025, down 17675.7 pp from a year earlier.
- Other working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -58.8% toward the trailing-twelve-month pace of +343700.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 2.19M USD
- Year-over-year change
- -52.5%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.19M | -52.5% |
| FY2024 | 2024-12-31 | 4.6M | +242.5% |
| FY2023 | 2023-12-31 | (3.23M) | -140.1% |
| FY2022 | 2022-12-31 | 8.04M | +198.0% |
| FY2021 | 2021-12-31 | (8.21M) | — |
Other Working Capital vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +343700.0% is the highest of 9, against a peer median of +6.5%.
- Other working capital amounts to 9544.4% of revenue for ALT, versus a peer median of 51.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.38M USD | -319.4% | -36.2% | 112.0% | |
| LTM Jun 2026 | $44.78M USD | -1818.8% | — | — | |
| LTM Mar 2026 | $36.58M USD | +102.5% | +204.1% | 51.5% | |
| LTM Mar 2026 | $16.41M USD | +7981.6% | — | 8.6% | |
| LTM Mar 2026 | $3.44M USD | +343700.0% | -35.2% | 9544.4% | |
| FY2025 | €3.15M EUR | +303.7% | — | 70.2% | |
| LTM Mar 2026 | $1.56M USD | -89.6% | — | 2.2% | |
| LTM Mar 2026 | $814.23K USD | +299.9% | — | — | |
| LTM Mar 2026 | $743K USD | -92.3% | +8.4% | — | |
| Peer median (excluding ALT) | — | +6.5% | +8.4% | 51.5% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (681K) |
| Stock-Based Compensation | 5.52M | 8.1M | 10.64M | 14.39M | 16.08M |
| Change in Working Capital | (251K) | 14.11M | (8.27M) | 4.48M | 6.75M |
| Accounts Receivables | 6.53M | 3.3M | (2.31M) | 1.74M | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.42M | 2.77M | (2.73M) | (1.86M) | 2.51M |
| Other Working Capital | (8.21M) | 8.04M | (3.23M) | 4.6M | 2.19M |
| Other Non-Cash Items | 13.03M | (578K) | 9.79M | (3.9M) | (1.7M) |
| Operating Cash Flow | (78.24M) | (62.59M) | (75.81M) | (79.85M) | (67.54M) |
| Capital Expenditures | (12.31M) | (126K) | (47K) | 0 | (11K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.59M) | (73.27M) | (88.63M) | (115.73M) | (285.45M) |
| Sales of Investments | 107.43M | 0 | 102.41M | 87.35M | 152.99M |
| Other Investing Activities | (195K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 87.52M | (73.4M) | 13.73M | (28.39M) | (132.47M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 33.92M |
| Common Stock Issued | 65.04M | 56.35M | 86.6M | 9.99M | 173.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 58K | 434K | (496K) | 50K | (709K) |
| Financing Cash Flow | 65.1M | 56.78M | 86.11M | 10.04M | 206.84M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.38M | (79.2M) | 24.03M | (98.19M) | 6.83M |
| Free Cash Flow | (90.55M) | (62.71M) | (75.86M) | (79.85M) | (67.55M) |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.